A study to examine the influence of repaglinide on the 'incretin effect' and oxidative damage associated with postprandial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2006-005331-25-GB

Enrollment

Registered

2007-01-01

Start date

2007-01-19

Completion date

Unknown

Last updated

2019-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type II Diabetes Mellitus

Interventions

Product Name: Novonorm Pharmaceutical Form: Tablet

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type II Diabetics treated with Metformin Non smokers aged between 40 - 70 years males & females No acute concurrent illness Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Patients with coronary heart disease Have proteinuria (albumin:creatnine ratio >30mg/mmol) and those with a serum creatinine >150mmol/l Patients taking vitamin supplementation

Design outcomes

Primary

Measure	Time frame
Secondary Objective: To replicate the associated improvement in plasma markers of oxidative stress previously observed with repaglinide and to further elucidate this mechanism in terms of postprandial glucose homeostasis and incretin effect ; Main Objective: The aim of this study is to explore the relationship between postprandial release of incretin hormones, glucose homeostasis and plasma markers related to oxidative stress and endothelial dysfunction in relation to the use of the postprandial glucose regulator drug, repaglinide. The work will allow us to investigate:- (i) For the first time, any effects of repaglinide on the release of incretin hormones (GLP-1 and GIP). Since both have effects on postprandial glucose homeostasis and ?-cell mediated insulin release, we speculate that repaglinide might contribute to improved glucose homeostasis via incretin release. (ii) For the first time in vivo, the association between incretin hormones and plasma markers of oxidative stress and endothelial dysfunction. ;Primary end point(s):	—

Measure

Time frame

Secondary Objective: To replicate the associated improvement in plasma markers of oxidative stress previously observed with repaglinide and to further elucidate this mechanism in terms of postprandial glucose homeostasis and incretin effect ; Main Objective: The aim of this study is to explore the relationship between postprandial release of incretin hormones, glucose homeostasis and plasma markers related to oxidative stress and endothelial dysfunction in relation to the use of the postprandial glucose regulator drug, repaglinide. The work will allow us to investigate:- (i) For the first time, any effects of repaglinide on the release of incretin hormones (GLP-1 and GIP). Since both have effects on postprandial glucose homeostasis and ?-cell mediated insulin release, we speculate that repaglinide might contribute to improved glucose homeostasis via incretin release. (ii) For the first time in vivo, the association between incretin hormones and plasma markers of oxidative stress and endothelial dysfunction. ;Primary end point(s):

—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026